What does this research mean for the field?

Leukocyte immunoglobulin-like receptor A3 (LILRA3) acts as a natural multi-LILRB signaling antagonist that counteracts myeloid-driven immunosuppression and restrains tumor growth. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To determine the immunoregulatory role of soluble leukocyte immunoglobulin-like receptor A3 (LILRA3) in myeloid-mediated immunosuppression and evaluate its antitumor potential.

September 10, 2026Cancer Immunology Research

Leukocyte immunoglobulin-like receptor A3 inhibits the activity of immunosuppressive myeloid cells

View Full Paper

Ask AI

Bookmark

Authors

MFMeng FangFudan University Shanghai Cancer Center XYXing YangShanghai University of Medicine and Health Sciences JXJingjing XieThe University of Texas Southwestern Medical Center

Discussion

Member takes

Overview

Translational study reveals that LILRA3 suppresses immunosuppressive myeloid cells and halts tumor growth in mouse models, highlighting its therapeutic potential as a multi-checkpoint antagonist.

Key Points

To determine the immunoregulatory role of soluble leukocyte immunoglobulin-like receptor A3 (LILRA3) in myeloid-mediated immunosuppression and evaluate its antitumor potential.
Quantified LILRA3 levels in serum and tumor tissues of cancer patients and analyzed associations with cytotoxic T cell infiltration and patient survival.
Investigated the molecular mechanism of LILRA3 binding to LILRB4 and endogenous LILRB ligands, assessing its effect on cytokine release and M2 macrophage polarization.
Evaluated the in vivo antitumor efficacy of LILRA3 using myeloid-specific LILRB2- and LILRB4-transgenic mice and humanized mouse tumor models.
Patient serum and tumor LILRA3 levels were significantly reduced, and higher systemic concentrations positively correlated with greater cytotoxic T cell infiltration and improved survival.
LILRA3 competitively bound LILRB4 and multiple endogenous LILRB ligands, blocking downstream inhibitory signaling, decreasing M2 macrophage polarization, and stimulating T cell proliferation.
LILRA3 administration significantly restrained tumor progression in both myeloid-specific LILRB2/LILRB4-transgenic mice and humanized mouse models.

Cite This Study

Fang et al. (2026) studied this question.

synapsesocial.com/papers/6aa27bcf58559d80afc7540e https://doi.org/10.1158/2326-6066.cir-26-0070

View Full Paper

Ask AI

Bookmark

September 10, 2026Cancer Immunology Research

Leukocyte immunoglobulin-like receptor A3 inhibits the activity of immunosuppressive myeloid cells

View Full Paper

Ask AI

Bookmark

Authors

MFMeng FangFudan University Shanghai Cancer Center XYXing YangShanghai University of Medicine and Health Sciences JXJingjing XieThe University of Texas Southwestern Medical Center

Discussion

Member takes

Overview

Translational study reveals that LILRA3 suppresses immunosuppressive myeloid cells and halts tumor growth in mouse models, highlighting its therapeutic potential as a multi-checkpoint antagonist.

Key Points

To determine the immunoregulatory role of soluble leukocyte immunoglobulin-like receptor A3 (LILRA3) in myeloid-mediated immunosuppression and evaluate its antitumor potential.
Quantified LILRA3 levels in serum and tumor tissues of cancer patients and analyzed associations with cytotoxic T cell infiltration and patient survival.
Investigated the molecular mechanism of LILRA3 binding to LILRB4 and endogenous LILRB ligands, assessing its effect on cytokine release and M2 macrophage polarization.
Evaluated the in vivo antitumor efficacy of LILRA3 using myeloid-specific LILRB2- and LILRB4-transgenic mice and humanized mouse tumor models.
Patient serum and tumor LILRA3 levels were significantly reduced, and higher systemic concentrations positively correlated with greater cytotoxic T cell infiltration and improved survival.
LILRA3 competitively bound LILRB4 and multiple endogenous LILRB ligands, blocking downstream inhibitory signaling, decreasing M2 macrophage polarization, and stimulating T cell proliferation.
LILRA3 administration significantly restrained tumor progression in both myeloid-specific LILRB2/LILRB4-transgenic mice and humanized mouse models.

Cite This Study

Fang et al. (2026) studied this question.

synapsesocial.com/papers/6aa27bcf58559d80afc7540e https://doi.org/10.1158/2326-6066.cir-26-0070

View Full Paper

Ask AI

Bookmark